Laidlaw analyst Yale Jen has downgraded iCAD (ICAD, Financial) from Buy to Hold after the company's announcement of its impending acquisition by DeepHealth, a subsidiary of RadNet (RNDT). This change in recommendation comes without a specified price target.
While the acquisition's valuation is described as "only modest," it presents iCAD shareholders with a timely opportunity for an investment exit amidst the current challenging macroeconomic conditions. The move is seen as a strategic decision in light of the present market turbulence.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for icad Inc (ICAD, Financial) is $3.50 with a high estimate of $3.50 and a low estimate of $3.50. The average target implies an upside of 14.01% from the current price of $3.07. More detailed estimate data can be found on the icad Inc (ICAD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, icad Inc's (ICAD, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for icad Inc (ICAD, Financial) in one year is $1.81, suggesting a downside of 41.04% from the current price of $3.07. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the icad Inc (ICAD) Summary page.
